In this insightful webinar, Dr Babar Basir (Henry Ford Heart and Vascular Institute, Detroit, MI, US) is joined by Dr Balimkiz Senman (Duke University Hospital, Boston, MA, US) and Prof Jacob Møller (Odense University Hospital, Odense, DE) to delve into the findings of the DanGer Shock trial, recently presented at the American College of Cardiology (ACC) Conference in April 2024. This session will provide a comprehensive review of the trial, highlighting both its strengths and limitations.
The speakers will examine the design, methodology, and significant outcomes, offering an in-depth interpretation of the results and comparing them with findings from previous related studies. Additionally, the speakers will explore the clinical implications of these findings to discuss the next steps and potential future research sparked by the trial's conclusions.
Visit Radcliffe Cardiology: www.radcliffec...
Visit Radcliffe Vascular: www.radcliffev...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliff...
Негізгі бет Cardiogenic Shock: Trial Updates and Future Directions
Пікірлер